For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Pramlintide (Symlin) is the only FDA-approved amylin analogue, approved in 2005 as an adjunct to mealtime insulin for type 1 and type 2 diabetes. It proved the amylin pathway is druggable in humans: slowing gastric emptying, suppressing postprandial glucagon, and reducing meal size through brainstem satiety signaling. In clinical trials, pramlintide reduced HbA1c by 0.2 to 0.6% and produced weight loss of 1 to 3 kg in diabetic populations, modest but meaningful given that insulin typically causes weight gain. In obesity trials without diabetes, weight loss reached 3.7 to 6.8% at higher doses. The critical limitation is pharmacokinetic: a half-life of approximately 48 minutes requires injection before every major meal (2 to 3 times daily), the same dosing burden as rapid-acting insulin. This dosing frequency severely limited clinical adoption and motivated the development of cagrilintide, a once-weekly amylin analogue now under FDA review as part of CagriSema.
The complete Pramlintide (Symlin) profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use